TrueAId
TrueAId, our trustworthy AI tool with 96% accuracy, revolutionizes the diagnosis and management of neurodevelopmental disorders by predicting the risk and progression of neurological impairment disorders in fetuses, offering a groundbreaking avenue for perinatal treatment with effective neurotrophic agents thus decreasing the incidence of fetal neurological impairment disorders consequently leading to a decrease in morbidity and mortality caused or attributed by this group of disorders.
The problem addressed by TrueAId centers on the current limitations in the early diagnosis and management of neurodevelopmental disorders in fetuses that affect 1 in 10.000 liveborn children. Traditional methods often fail to detect these disorders at a stage when interventions could be most effective. Without early detection, treatment options are limited and less effective, potentially leading to long-term impacts on the child's development and quality of life. TrueAId offers a solution by providing an advanced AI-driven tool that can predict the risk and progression of neurological disorders early in the fetal stage, thereby opening up new possibilities for timely and potentially transformative perinatal intervention.
TrueAId solution is driven by a proven need and commitment to bring the AI technology to actual use in obstetrics and gynecology for prevention and detection of neurodevelopmental disorders in order to improve the well-being of affected populations. TrueAId is in line with EU, UN and WHO principles, which recognize the importance of incorporating digital technologies into existing healthcare systems that would bring demonstrable improvements.
.
